You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antiretroviral therapy, HIV infections, cabotegravir, rilpivirine, long-acting intramuscular injection,

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV Trial (DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA)

Not yet recruiting
  • HIV Infections
  • (no location specified)
Jun 13, 2023

HIV-positive People, Treated With Long Acting Antiretroviral

Active, not recruiting
  • HIV Infections
  • Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL
  • Milan, Italy
    Ospedale San Raffaele Scientific Institute
Dec 15, 2022

HIV Trial in Worldwide (Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Long-Acting Injectable Cabotegravir (CAB LA))

Recruiting
  • HIV Infections
  • Oral Cabotegravir (CAB)
  • +4 more
  • La Jolla, California
  • +30 more
Feb 2, 2023

HIV Trial in Glendale (Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir extended release suspension for injection

Completed
  • HIV Infections
  • Cabotegravir Tablets
  • +3 more
  • Glendale, California
    GSK Investigational Site
Feb 14, 2022

HIV-1-infection Trial (Cabotegravir/Rilpivirine, Antiretroviral)

Recruiting
  • HIV-1-infection
  • Kisumu, Kenya
  • +6 more
Feb 1, 2023

Long-acting Injectable Cabotegravir + Rilpivirine

Not yet recruiting
  • Patient Satisfaction
  • +3 more
    • Santiago, Region Metropolitana, Chile
      CICUC
    Apr 18, 2023

    HIV-1-infection, HIV, HIV I Infection Trial (CAB + RPV)

    Not yet recruiting
    • HIV-1-infection
    • +2 more
    • CAB + RPV
    • (no location specified)
    Nov 16, 2022

    Implementation and Delivery of Cabotegravir Long Acting

    Not yet recruiting
    • HIV Infections
    • Cabotegravir Injection [Apretude]
    • Seattle, Washington
    • +1 more
    May 16, 2023

    HIV, Contraception, Drug-drug Interaction Trial in Eldoret (Cabotegravir/ Rilpivirine, Etonogestrel (ETG) implant, Intramuscular

    Recruiting
    • HIV Infections
    • +2 more
    • Cabotegravir/ Rilpivirine
    • +4 more
    • Eldoret, Kenya
      Academic Model Providing Access to Healthcare (AMPATH) Moi Teach
    Mar 30, 2022

    HIV Trial in Boston (CAB-RPV LA, Standard treatment within an HIV clinic)

    Enrolling by invitation
    • HIV Infections
    • CAB-RPV LA
    • Standard treatment within an HIV clinic
    • Boston, Massachusetts
    • +1 more
    Feb 24, 2022

    Human Immunodeficiency Virus Type 1 (HIV-1) Trial in Worldwide (Cabotegravir Injectable Suspension, Rilpivirine Injectable

    Completed
    • Human Immunodeficiency Virus Type 1 (HIV-1)
    • Cabotegravir Injectable Suspension
    • Rilpivirine Injectable Suspension
    • Bakersfield, California
    • +31 more
    May 31, 2023

    Oregon PrEP at Home Study

    Not yet recruiting
    • HIV/AIDS
    • Cabotegravir Injection
    • Portland, Oregon
      Oregon Health & Science University
    Jul 15, 2023

    HIV Trial in Canada, United States (CAB LA, RPV LA, RPV)

    Active, not recruiting
    Has Results
    • HIV Infections
    • CAB LA
    • +3 more
    • Phoenix, Arizona
    • +29 more
    Jan 22, 2023

    Human Immunodeficiency Virus Type 1 (HIV-1) Trial in Worldwide (Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine -

    Active, not recruiting
    • Human Immunodeficiency Virus Type 1 (HIV-1)
    • Cabotegravir - Injectable Suspension (CAB LA)
    • Rilpivirine - Injectable Suspension (RPV LA)
    • Macon, Georgia
    • +29 more
    May 31, 2023

    HIV Trial in Puerto Rico, United States (Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB)

    Recruiting
    • HIV Infections
    • Standard of Care (SOC) Oral ART
    • +6 more
    • Birmingham, Alabama
    • +34 more
    Dec 1, 2021

    HIV Trial in Rio De Janeiro (Cabotegravir Injection)

    Not yet recruiting
    • HIV Infections
    • Cabotegravir Injection
    • Rio De Janeiro, Brazil
      Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ
    Aug 23, 2022

    HIV Trial in New Zealand, United States (Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL)

    Recruiting
    • HIV Infections
    • Cabotegravir sodium (Oral Lead In)
    • +6 more
    • Orlando, Florida
    • +4 more
    Mar 29, 2022

    Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy Trial in Seattle (TLC-ART)

    Recruiting
    • Human Immunodeficiency Virus
    • +2 more
    • Seattle, Washington
      UW Positve Research, Harborview Medical Center
    May 8, 2023

    HIV Trial in Worldwide (Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets)

    Active, not recruiting
    • HIV Infections
    • Cabotegravir Tablets
    • +4 more
    • Bakersfield, California
    • +116 more
    Jan 22, 2023

    HIV Trial (Teropavimab, Zinlirvimab, Lenacapavir Tablet)

    Not yet recruiting
    • HIV Infections
    • Teropavimab
    • +4 more
    • (no location specified)
    Feb 6, 2023

    Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (GSK744, GSK744 LA, TMC278 LA)

    Active, not recruiting
    Has Results
    • Infection, Human Immunodeficiency Virus
    • HIV Infections
    • Birmingham, Alabama
    • +49 more
    Dec 26, 2022

    HIV Trial in Los Angeles (Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App)

    Enrolling by invitation
    • HIV Infections
    • Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App
    • Los Angeles, California
      AIDS Healthcare Foundation
    Oct 27, 2021

    Satisfaction of HIV-infected Patients Treated With

    Not yet recruiting
    • HIV Infections
    • satisfaction survey
    • (no location specified)
    Jan 16, 2023

    HIV-1-infection Trial in Worldwide (Once daily CAB tablet + RPV tablet, Long acting CAB injectable + long acting RPV injectable)

    Not yet recruiting
    • HIV-1-infection
    • Once daily CAB tablet + RPV tablet
    • Long acting CAB injectable + long acting RPV injectable
    • Atlanta, Georgia
    • +11 more
    Dec 13, 2022

    Human Immunodeficiency Virus, Opioid Use Disorder Trial in Providence (Combined LAI Treatment: Cabenuva and Sublocade)

    Recruiting
    • Human Immunodeficiency Virus
    • Opioid Use Disorder
    • Combined LAI Treatment: Cabenuva and Sublocade
    • Providence, Rhode Island
      Rhode Island Hospital
    Aug 7, 2023